Volume 21, Issue 4 (Winter 2024)
Sci J Iran Blood Transfus Organ 2024, 21(4): 346-356 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hedayati-Moghaddam M. Is cupping therapy a significant risk factor for transfusion-transmitted infections? Evidence from a systematic review. Sci J Iran Blood Transfus Organ 2024; 21 (4) :346-356
URL: http://bloodjournal.ir/article-1-1542-en.html
URL: http://bloodjournal.ir/article-1-1542-en.html
Abstract: (422 Views)
Abstract
Background and Objectives
Cupping therapy (Hijama), as a common method of treatment in the world, could carry a significant risk of infections by bloodborne pathogens. We aimed to review systematically scientific reports on the relationship between cupping practices and bloodborne infections.
Materials and Methods
In this systematic review, international and local databases were searched using relevant keywords. All original citations published in English or Persian up to March 2024 were included. No limitations were applied to study design, sample size, publication date, or cupping techniques.
Results
After screenintg the titles and abstracts of 630 studies retrieved from the initial search, the full texts of 67 non-duplicate documents were reviewed. Of these, 42 articles were excluded for various reasons. A manual search of the references from the retrieved papers yielded 6 additional articles, resulting in a total of 29 studies that fulfilled the inclusion criteria after excluding two overlapping citations. Among the 15 surveys that assessed HBV infection, only 3 demonstrated a positive association between a history of cupping and this infection using multivariate analysis; the reported odds ratios ranged 3.8 to 7.3. Regarding HCV infection, 2 of 13 investigations confirmed a positive correlation with cupping therapy in multivariate regression analysis; the reported odds ratios were 2.3 and 2.4. No reports indicated a significant relationship between cupping therapy and HDV, HIV, or HTLV-1 infections.
Conclusions
This systematic review revealed that there is insufficient evidence regarding the role of cupping in the spread of bloodborne infections. It is recommended to conduct large-scale and longitudinal studies to find if this traditional practice is a significant risk factor for infection.
Background and Objectives
Cupping therapy (Hijama), as a common method of treatment in the world, could carry a significant risk of infections by bloodborne pathogens. We aimed to review systematically scientific reports on the relationship between cupping practices and bloodborne infections.
Materials and Methods
In this systematic review, international and local databases were searched using relevant keywords. All original citations published in English or Persian up to March 2024 were included. No limitations were applied to study design, sample size, publication date, or cupping techniques.
Results
After screenintg the titles and abstracts of 630 studies retrieved from the initial search, the full texts of 67 non-duplicate documents were reviewed. Of these, 42 articles were excluded for various reasons. A manual search of the references from the retrieved papers yielded 6 additional articles, resulting in a total of 29 studies that fulfilled the inclusion criteria after excluding two overlapping citations. Among the 15 surveys that assessed HBV infection, only 3 demonstrated a positive association between a history of cupping and this infection using multivariate analysis; the reported odds ratios ranged 3.8 to 7.3. Regarding HCV infection, 2 of 13 investigations confirmed a positive correlation with cupping therapy in multivariate regression analysis; the reported odds ratios were 2.3 and 2.4. No reports indicated a significant relationship between cupping therapy and HDV, HIV, or HTLV-1 infections.
Conclusions
This systematic review revealed that there is insufficient evidence regarding the role of cupping in the spread of bloodborne infections. It is recommended to conduct large-scale and longitudinal studies to find if this traditional practice is a significant risk factor for infection.
References
1. Adelineghad F. Hijamat. Zahedan J Res Med Sci 2011; 13(1): 55-7. [Article in Farsi]
2. Nimrouzi M, Mahbodi A, Jaladat AM, Sadeghfard A, Zarshenas MM. Hijamat in Traditional Persian Medicine: Risks and Benefits. J Evid Based Complementary Altern Med 2014; 19(2): 128-36. [DOI:10.1177/2156587214524578] [PMID]
3. Qureshi NA, Ali GI, Abushanab TS, El-Olemy AT, Alqaed MS, El-Subai IS, Al-Bedah AMN. History of cupping (Hijama): a narrative review of literature. J Integr Med 2017; 15(3): 172-81. [DOI:10.1016/S2095-4964(17)60339-X] [PMID]
4. Gharah Baghian A, Mehran M, Karimi G, Vafaeian V, Tabrizi Namini M. Hijama through the passage of time. Sci J Iran Blood Transfus Organ 2009; 6(2): 147-58. [Article in Farsi]
5. Chatraee Azizabadi M. Background of phlebotomy (cupping) in Iran and its role on human health. Health Syst Res 2012; 8(7(Supplement): 1107-116. [Article in Farsi]
6. Tehrani Banihashemi SA, Asgharifard H, Haghdoost AA, Barghmadi M, Mohammadhosseini N. The use of Complementary/Alternative Medicine among the general population in Tehran, Iran. Payesh J (Health Monit) 2008; 7(4): 355-62. [Article in Farsi]
7. Mirrezaie SM, Saber HR, Nadali F, Abbasian A, Hajibeigi B, Mirrezaie SR. Exposure with minor risk factors among blood donors in Tehran province, Iran: A cohort study. J Isfahan Med School 2015; 33(345): 1261-71. [Article in Farsi]
8. Maghsudlu M, Makipour M, Nasizadeh S. Evaluation of deferral causes of blood donors and relevant factors. Sci J Iran Blood Transfus Organ 2006; 3(1): 9-16. [Article in Farsi]
9. Abou Alghasemi H, Kheirkhahi M, Hosseini SM. Survey of the reasons for the deferral of blood donors in Tehran blood transfusion center. Hakim Res J 2002; 5(2): 119-25. [Article in Farsi]
10. Nouri M, Maghsudlu M, Etemad K. The return rate of blood donors during three years after temporary deferral in Tabriz. Sci J Iran Blood Transfus Organ 2018; 15(4): 250-6. [Article in Farsi]
11. Birjandi F, Gharehbaghian A, Delavari A, Rezaie N, Maghsudlu M. Blood donor deferral pattern in Iran. Arch Iran Med 2013; 16(11): 657-60.
12. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med 2009; 12(3): 225-31.
13. Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat Mon 2011; 11(5): 346-50.
14. Vossoughinia H, Taghi Shakeri M, Mokhtari Amirmajdi E, Ravan bakhsh F, Abedini S. Risk Factors for Hepatitis B and C in 400 Blood Donor Volunteers in Mashhad During 2003-2007: A Case-control Study. Intern Med Today 2010; 15(4): 68-75. [Article in Farsi]
15. Mudardum AH, Mohammed AA. Prevalence and Risk Factors for Hepatitis B Infection among Pregnant Women attending Antenatal Clinic in UM Dafog Area, South Darfur State, Sudan. Sudan J Med Sci 2019; 14(3): 116-25. [DOI:10.18502/sjms.v14i3.5211]
16. Sali S, Bashtar R, Alavian SM. Risk Factors in Chronic Hepatitis B Infection: A Case-control Study. Hepat Mon 2005; 5(4): 109-15.
17. Al-Nwany NT, Ahmad N, Mohammed Nawi A, Hassan MR, Hod R, Baharom M. Seroprevalence of Hepatitis B Virus Infection and Its Associated Factors Among Blood Donors in Yemen. Malays J Med Sci 2021; 28(5): 54-63. [DOI:10.21315/mjms2021.28.5.5] [PMID] []
18. Raslan E, AbdAllah M, Soliman S. The prevalence and determinants of hepatitis B among Egyptian adults: a further analysis of a country-representative survey. Egypt Liver J 2022; 12(1): 46. [DOI:10.1186/s43066-022-00207-x]
19. Heiza M, Elmola K, Salama B. Unsafe Practices Associated with HCV Infection Among Adults: A Case Control Study. Int J Prev Med 2021; 12: 60. [DOI:10.4103/ijpvm.IJPVM_94_20] [PMID] []
20. Babaei A, Safarpour A, Fattahi M, Ahmadi V. Epidemiology of Hepatitis C Virus Infection Among 1,959 Patients in Shiraz, Southern Iran, Between 1991 and 2016. Arch Clin Infect Dis 2020; 15(1): e98849. [DOI:10.5812/archcid.98849]
21. Ranjbar Kermani F, Hosseini KM, Kafi-Abad SA, Maghsudlu M, Sharifi Z, Mansournia MA, et al. Update on transmission modes of hepatitis C virus among volunteer Iranian blood donors: Analysis of a matched case-control study by penalized conditional logistic regression. Hepat Mon 2018; 18(10): e69395. [DOI:10.5812/hepatmon.69395]
22. Al Humayed SM, El-Mekki AA, Mahfouz AA. Hepatitis C virus infection in southwestern Saudi Arabia: Are we still in the plateau phase? J Med Virol 2017; 89(5): 867-71. [DOI:10.1002/jmv.24712] [PMID]
23. Tajbakhsh E, Paiedar F, Seroepidemiological study of HCV infections in Shahrekord jail prisoners. J Microbial World 2008; 1(1): 23-8. [Article in Farsi]
24. Abedi F, Madani H, Asadi A, Nejatizadeh A.Significance of blood-related high-risk behaviors and horizontal transmission of hepatitis B virus in Iran. Arch Virol 2011; 156(4): 629-35. [DOI:10.1007/s00705-010-0902-y] [PMID]
25. Ageely H, Mahfouz M, Gaffar A, Elmakki E, Elhassan I, Yassin AO, Bani I. Prevalence and Risk Factors of Hepatitis B Virus in Jazan Region, Saudi Arabia: Cross-Sectional Health Facility Based Study. Health 2015; 07: 459-65. [DOI:10.4236/health.2015.74054]
26. Al-Waleedi AA, Khader YS. Prevalence of hepatitis B and C infections and associated factors among blood donors in Aden City, Yemen. East Mediterr Health J 2012; 18(6): 624-9. [DOI:10.26719/2012.18.6.624] [PMID]
27. Alavian S, Assari S, Manzoori-Joybari H, Moghani Lankarani M, Doroudi T, Hajibeigi B, Hajarizadeh B. Frequency and risk factors of hepatitis D virus in hepatitis B patients. Govaresh 2005; 10: 21-6. [Article in Farsi]
28. Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J 2011; 13(6): 424-7.
29. Javanmard D, Alavian SM, Abedi F, Namaei MH, Asghari A, Ziaee M. High prevalence of hepatitis B virus infection in the village of esfandiar in South Khorasan province, Iran. Hepat Mon 2018; 18(8): e65473. [DOI:10.5812/hepatmon.65473]
30. Keyvani H, Sohrabi M, Zamani F, Poustchi H, Ashrafi H, Saeedian F, et al. A population based study on hepatitis B virus in northern iran, amol. Hepat Mon 2014; 14(8): e20540. [DOI:10.5812/hepatmon.20540] [PMID] []
31. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52(3): 172-6. [DOI:10.1016/j.jcv.2011.07.004] [PMID]
32. Salehi M, Hedayati-Moghaddam MR, Moradian Evari AA. Prevalence of Hepatitis B Serological Markers Among People Who Referred to a Great Laboratory in Neyshabur, Northeast of Iran. Int J Infect 2019; 6(3): e89914. [DOI:10.5812/iji.89914]
33. Tajbakhsh E, Yaghobi R, Vahedi AR. A serological survey on hepatitis C virus Antibody in blood donors with an ELISA method. Tehran Univ Med J 2007; 65(8): 69-73. [Article in Farsi]
34. Zali MR, Aghazadeh R, Amiri A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: Is it a serious problem? Arch Iran Med 2001; 4(3): 115-9.
35. Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, et al. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011). Hepat Mon 2013; 13(12): e13313. [DOI:10.5812/hepatmon.13313]
36. Ziaee M, Ebrahimzadeh A, Azarkar Z, Namaei MH, Saburi A, Fereidouni M, et al. Seroprevalence and Risk Factors for Hepatitis B in an Adult Population: The First Report from Birjand, South Khorasan, Iran. Hepat Mon 2016; 16(9): e36452. [DOI:10.5812/hepatmon.36452]
37. Alswaidi FM, O'Brien SJ. Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors? J Epidemiol Community Health 2010; 64(11): 989-97. [DOI:10.1136/jech.2009.093302] [PMID]
38. Hedayati-Moghaddam MR, Tehranian F, Bayati M. Human T-Lymphotropic Virus Type I (HTLV-1) Infection among Iranian Blood Donors: First Case-Control Study on the Risk Factors. Viruses 2015; 7(11): 5736-45. [DOI:10.3390/v7112904] [PMID] []
39. Mandoh SS, Ayman K, Elbardakheny A, Raaft H, Ibrahim AA, Alshaikh RA, Mansour FR. A cross sectional study of the risk factors of hepatitis C infection in North Egypt. Virusdisease 2021; 32(1): 22-8. [DOI:10.1007/s13337-020-00639-2] [PMID] []
40. Mohd Suan MA, Said SM, Lim PY, Azman AZF, Abu Hassan MR. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case- control study. PLoS One 2019; 14(10): e0224459. [DOI:10.1371/journal.pone.0224459] [PMID] []
41. Nazzal Z, Sobuh I. Risk factors of hepatitis B transmission in northern Palestine: a case-control study. BMC Res Notes 2014; 7: 190. [DOI:10.1186/1756-0500-7-190] [PMID] []
42. Rezaei N, Amini-Kafiabad S, Maghsudlu M, Abolghasemi H. Risk factor analysis of hepatitis C virus seropositivity in Iranian blood donors: a case-control study. Transfusion 2016; 56(7): 1891-8. [DOI:10.1111/trf.13660] [PMID]
43. El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989-2013): do they differ in Egypt? Liver Int 2015; 35(2): 489-501. [DOI:10.1111/liv.12617] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
